<- Go Home
Precipio, Inc.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Market Cap
$55.7M
Volume
20.1K
Cash and Equivalents
$3.1M
EBITDA
-$129.0K
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$12.0M
Profit Margin
44.11%
52 Week High
$33.63
52 Week Low
$14.04
Dividend
N/A
Price / Book Value
3.77
Price / Earnings
-44.65
Price / Tangible Book Value
12.91
Enterprise Value
$56.2M
Enterprise Value / EBITDA
151.55
Operating Income
-$1.5M
Return on Equity
8.98%
Return on Assets
-4.81
Cash and Short Term Investments
$3.1M
Debt
$3.6M
Equity
$14.8M
Revenue
$27.2M
Unlevered FCF
$1.4M
Sector
Health Care Providers and Services
Category
N/A